

30 November 2021

## Life Fund

## CM Fidelity Wealth Builder


The fund has merged into Fidelity Open World Fund on 22nd February 2019; the Fund's aim has changed, however risk profile remains the same. We will continue to refer to Fidelity Wealth Builder in our literature. Please see Fidelity website for full fund aims and objectives - [fidelity.co.uk](http://fidelity.co.uk)

This document is provided for the purpose of information only. This factsheet is intended for individuals who are familiar with investment terminology. Please contact your financial adviser if you need an explanation of the terms used. This material should not be relied upon as sufficient information to support an investment decision. The portfolio data on this factsheet is updated on a quarterly basis.

### Asset Allocation (as at 31/10/2021)



### Regional Breakdown (as at 31/10/2021)



The composition of asset mix and asset allocation may change at any time and exclude cash unless otherwise stated

### Fund Aim

This Fund targets an average annual return of 7% after the deduction of ongoing fund charges, over a typical market cycle of 5-7 years. The Fund has a large exposure to equities meaning that it is likely to experience short-term price fluctuations in line with these markets and an investor may not get back the full amount invested. Please see the Fidelity website for full details


### Basic Fund Information

Fund Launch Date	13/01/2005
Fund Size	£3.4m
Sector	ABI Global Equities
ISIN	GB00B04QPP38
MEX ID	CMFWL
SEDOL	B04QPP3
Manager Name	Chris Forgan, Charlotte Harington
Manager Since	01/01/2020, 01/01/2020

### Top Ten Holdings

<b>(as at 31/10/2021)</b>	
FIDELITY NORTH AMERICA EQUITY FUND I-ACCUUSD	34.5%
FIDELITY EUROPE EX-UK EQUITY FUND I-ACC-EURO	16.4%
XTRACKERS S&P 500 SWAP UCITS E	8.2%
FIDELITY ASIA PACIFIC EX-JAPAN EQUITY FUND IACC-USD	7.7%
FIDELITY GLOBAL EMERGING MARKETS EQUITY FUND I-ACC-USD	7.5%
FIDELITY UK EQUITY FUND I-ACC-GBP	6.8%
FIDELITY JAPAN EQUITY FUND I-ACC-JPY	6.0%
IXU UTILITIES SELECT SECTOR INDX_CFD	3.5%
FIDELITY GLOBAL DIVIDEND FUND W ACCUMULATION SHARES	2.5%
BGF-US BASIC VAL-I2 USD	2.3%
<b>TOTAL</b>	<b>95.4%</b>

## Past Performance



■ CM Fidelity Wealth Builder

■ ABI Global Equities

Past performance is not a guide to future performance. Investment value and income from it may fall as well as rise, as a result of market and currency movements. You may not get back the amount originally invested.

## Discrete Performance

	30/09/2020 - 30/09/2021	30/09/2019 - 30/09/2020	30/09/2018 - 30/09/2019	30/09/2017 - 30/09/2018	30/09/2016 - 30/09/2017
CM Fidelity Wealth Builder	21.1%	-1.8%	4.8%	5.9%	10.9%
ABI Global Equities	20.5%	2.0%	4.4%	8.7%	12.5%

Information is shown as unavailable if prior to the launch of fund.

## Cumulative Performance

	30/10/2021 - 30/11/2021	30/08/2021 - 30/11/2021	30/11/2020 - 30/11/2021	30/11/2018 - 30/11/2021	30/11/2016 - 30/11/2021
CM Fidelity Wealth Builder	1.3%	1.0%	15.3%	30.4%	47.4%
ABI Global Equities	1.1%	1.1%	15.9%	37.1%	57.6%
Quartile	2	3	3	3	3

Source: FE fundinfo as at 30/11/2021

Performance figures are in £ Sterling on a single pricing basis, with income (where applicable) reinvested net of UK tax and net of total annual fund charges. These figures do not include any initial charge or other product charge(s) that may be applicable.

## Fund Rating Information

Overall Morningstar Rating -

Morningstar Analyst Rating -

FE fundinfo Crown Rating 5

The FE fundinfo Crown Rating relates to this fund. However, the Morningstar ratings are based on the underlying fund. These are supplied by the respective independent ratings agencies and are the latest available at the time this factsheet was issued. Past performance is not a reliable indicator of future results.

## Other Information

The views, opinions and forecasts expressed in this document are those of the fund manager. Investment markets and conditions can change rapidly and as such the views expressed should not be taken as statement of fact, nor should reliance be placed on these views when making investment decisions.

For further information contact your local sales office or phone Customer Services on 0345 030 6243 (Life and Pensions) 0345 300 2244 (OEIC). Details are also available at [www.clericalmedical.co.uk](http://www.clericalmedical.co.uk)

Not all products have access to this fund, please refer to the relevant product literature. Full terms and conditions are available on request from us using the contact details provided. Charges, terms and the selection of funds we make available may change. Information on the general and specific risks associated with investing in this fund is available in the relevant fund guide, or KIID where applicable. We may change the investment approach rating for the fund. All information is sourced from Scottish Widows or the relevant fund management group unless otherwise stated.

## Quarterly Fund Manager Review

The fund generated positive absolute returns over the quarter and outperformed the average fund in its Investment Association (IA) peer group. Within growth assets, most of the regional equity exposures, except Pacific ex-Japan, contributed to performance. The underlying managers' holdings in the information technology, financials and health care sectors boosted performance. At a stock level, the position in investment bank Morgan Stanley continued to rally on the back of strong earnings announced in July, with the wealth management and investment management businesses registering growth. At the portfolio level, the long position in the Financial Select Sector Index added value, while the short position in the S&P Homebuilders Select Industry Index weighed on returns. The underlying managers' holdings in the industrials, energy and financials sectors enhanced gains. At the portfolio level, a position in a third-party value fund and a long position in the FTSE 100 index added value. At a stock level, the holding in Novo Nordisk advanced after it reported solid second quarter results and upgraded its full year revenue guidance. The upgrade was driven by strong sales of newer drugs, and consistent sales growth in its North America and international markets. Shares in Headlam rallied following a strong trading update, where it indicated that group revenues had improved to pre-COVID-19 levels. The holding in gold weighed on returns, while the allocation to cash added some value.

**Chris Forgan, Charlotte Harington 30/09/2021**

The views, opinions and forecasts expressed in this document are those of the fund management house. Investment markets and conditions can change rapidly and as such the views expressed should not be taken as statements of fact, nor should reliance be placed on these views when making investment decisions.